{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T06:36:30Z","timestamp":1785393390599,"version":"3.55.0"},"reference-count":25,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,25]],"date-time":"2025-03-25T00:00:00Z","timestamp":1742860800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003399","name":"Science and Technology Commission of Shanghai Municipality","doi-asserted-by":"publisher","award":["23S11903300"],"award-info":[{"award-number":["23S11903300"]}],"id":[{"id":"10.13039\/501100003399","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.esmoop.2025.105059","type":"journal-article","created":{"date-parts":[[2025,5,12]],"date-time":"2025-05-12T14:39:37Z","timestamp":1747060777000},"page":"105059","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Novel TROP2 antibody\u2013drug conjugates for treatment of HER2-negative metastatic breast cancer patients with brain metastases: a promising option\u2606"],"prefix":"10.1016","volume":"10","author":[{"given":"J.","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Bai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Z.","family":"Tong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"X.","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1158-0357","authenticated-orcid":false,"given":"Q.","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"X.","family":"Xing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"X.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.esmoop.2025.105059_bib1","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1200\/OP.23.00794","article-title":"Breast cancer brain metastasis: a comprehensive review","volume":"20","author":"Raghavendra","year":"2024","journal-title":"JCO Oncol Pract"},{"key":"10.1016\/j.esmoop.2025.105059_bib2","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.1086821","article-title":"Systemic treatments for breast cancer brain metastasis","volume":"12","author":"Chen","year":"2023","journal-title":"Front Oncol"},{"issue":"11","key":"10.1016\/j.esmoop.2025.105059_bib3","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1016\/j.annonc.2021.07.016","article-title":"EANO\u2013ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up of patients with brain metastasis from solid tumours","volume":"32","author":"Le Rhun","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmoop.2025.105059_bib4","first-page":"1","article-title":"Central nervous system metastases from triple-negative breast cancer: current treatments and future prospective","volume":"14","author":"Kadamkulam Syriac","year":"2022","journal-title":"Breast Cancer"},{"key":"10.1016\/j.esmoop.2025.105059_bib5","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.breast.2020.11.021","article-title":"Incidence, risk factors and survival of patients with brain metastases at initial metastatic breast cancer diagnosis in China","volume":"55","author":"Li","year":"2021","journal-title":"Breast"},{"issue":"12","key":"10.1016\/j.esmoop.2025.105059_bib6","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1016\/j.annonc.2020.09.010","article-title":"5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)","volume":"31","author":"Cardoso","year":"2020","journal-title":"Ann Oncol"},{"issue":"23","key":"10.1016\/j.esmoop.2025.105059_bib7","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1200\/JCO.22.00520","article-title":"Management of advanced human epidermal growth factor receptor 2-positive breast cancer and brain metastases: ASCO guideline update","volume":"40","author":"Ramakrishna","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.esmoop.2025.105059_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2023.102521","article-title":"Molecular aspects of brain metastases in breast cancer","volume":"114","author":"Tomasik","year":"2023","journal-title":"Cancer Treat Rev"},{"issue":"6","key":"10.1016\/j.esmoop.2025.105059_bib9","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s12032-023-02047-0","article-title":"Biology of breast cancer brain metastases and novel therapies targeting the blood brain barrier: an updated review","volume":"40","author":"Zhao","year":"2023","journal-title":"Med Oncol"},{"issue":"6","key":"10.1016\/j.esmoop.2025.105059_bib10","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1038\/s41571-023-00756-z","article-title":"Understanding the activity of antibody-drug conjugates in primary and secondary brain tumours","volume":"20","author":"Mair","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.esmoop.2025.105059_bib11","article-title":"Cancer Clinical Trial Eligibility Criteria","year":"2020","journal-title":"Brain Metastases Guidance for Industry"},{"issue":"22","key":"10.1016\/j.esmoop.2025.105059_bib12","doi-asserted-by":"crossref","first-page":"5612","DOI":"10.3390\/cancers14225612","article-title":"Systemic therapy for patients with HER2-positive breast cancer and brain metastases: a systematic review and meta-analysis","volume":"14","author":"Werter","year":"2022","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.esmoop.2025.105059_bib13","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s11060-023-04276-9","article-title":"Systematic review of the management of brain metastases from hormone receptor positive breast cancer","volume":"162","author":"Jusino","year":"2023","journal-title":"J Neurooncol"},{"issue":"9","key":"10.1016\/j.esmoop.2025.105059_bib14","article-title":"Phase 1a study of ESG401, a Trop2 antibody-drug conjugate, in patients with locally advanced\/metastatic solid tumors","volume":"5","author":"Wang","year":"2024","journal-title":"Cell Rep Med"},{"issue":"1","key":"10.1016\/j.esmoop.2025.105059_bib15","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/s10549-017-4107-x","article-title":"Brain metastasis in patients with metastatic breast cancer in the real world: a single-institution, retrospective review of 12-year follow-up","volume":"162","author":"Matsuo","year":"2017","journal-title":"Breast Cancer Res Treat"},{"issue":"15","key":"10.1016\/j.esmoop.2025.105059_bib16","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1200\/JCO.2017.35.15_suppl.1075","article-title":"Trop2 gene expression (Trop2e) in primary breast cancer (BC): correlations with clinical and tumor characteristics","volume":"35","author":"Vidula","year":"2017","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.esmoop.2025.105059_bib17","doi-asserted-by":"crossref","first-page":"2754","DOI":"10.1158\/2159-8290.CD-22-0837","article-title":"Trastuzumab deruxtecan in HER2-positive metastatic breast cancer patients with brain metastases: a DESTINY-Breast01 subgroup analysis","volume":"12","author":"Jerusalem","year":"2022","journal-title":"Cancer Discov"},{"issue":"suppl 4","key":"10.1016\/j.esmoop.2025.105059_bib18","first-page":"PD13","article-title":"Abstract PD13-07: Subgroup analysis of patients with brain metastases from the phase 3 ASCENT study of sacituzumab govitecan versus chemotherapy in metastatic triple-negative breast cancer","volume":"81","author":"Di\u00e9ras","year":"2021","journal-title":"Cancer Res"},{"issue":"16_suppl","key":"10.1016\/j.esmoop.2025.105059_bib19","doi-asserted-by":"crossref","first-page":"8593","DOI":"10.1200\/JCO.2024.42.16_suppl.8593","article-title":"Intracranial efficacy of datopotamab deruxtecan (Dato-DXd) in patients (pts) with previously treated advanced\/metastatic non-small cell lung cancer (a\/m NSCLC) with actionable genomic alterations (AGA): results from TROPION-Lung05","volume":"42","author":"Lisberg","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.esmoop.2025.105059_bib20","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1007\/s10549-014-3039-y","article-title":"TBCRC 018: phase II study of iniparib in combination with irinotecan to treat progressive triple negative breast cancer brain metastases","volume":"146","author":"Anders","year":"2014","journal-title":"Breast Cancer Res Treat"},{"issue":"11","key":"10.1016\/j.esmoop.2025.105059_bib21","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1016\/j.jtho.2021.06.020","article-title":"Outcomes with pembrolizumab plus platinum-based chemotherapy for patients with NSCLC and stable brain metastases: pooled analysis of keynote-021, -189, and -407","volume":"16","author":"Powell","year":"2021","journal-title":"J Thorac Oncol"},{"issue":"20","key":"10.1016\/j.esmoop.2025.105059_bib22","doi-asserted-by":"crossref","first-page":"5310","DOI":"10.1158\/1078-0432.CCR-20-1764","article-title":"A phase II study of abemaciclib in patients with brain metastases secondary to hormone receptor\u2013positive breast cancer","volume":"26","author":"Tolaney","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"suppl 9","key":"10.1016\/j.esmoop.2025.105059_bib23","article-title":"Abstract PO3-15-12: Expression and co-expression patterns of TROP2 and HER2 in breast cancer: implications for bispecific antibody-drug conjugate therapy","volume":"84","author":"Onishi","year":"2024","journal-title":"Cancer Res"},{"issue":"6","key":"10.1016\/j.esmoop.2025.105059_bib24","doi-asserted-by":"crossref","first-page":"4527","DOI":"10.18632\/oncotarget.2886","article-title":"A phase I trial of high dose gefitinib for patients with leptomeningeal metastases from non-small cell lung cancer","volume":"6","author":"Jackman","year":"2015","journal-title":"Oncotarget"},{"issue":"33","key":"10.1016\/j.esmoop.2025.105059_bib25","doi-asserted-by":"crossref","first-page":"3753","DOI":"10.1200\/JCO.2017.74.4102","article-title":"Modernizing clinical trial eligibility criteria: recommendations of the American Society of Clinical Oncology-Friends of Cancer Research Organ Dysfunction, Prior or Concurrent Malignancy, and Comorbidities Working Group","volume":"35","author":"Lichtman","year":"2017","journal-title":"J Clin Oncol"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702925009287?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702925009287?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T10:44:36Z","timestamp":1762598676000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2059702925009287"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":25,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["S2059702925009287"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2025.105059","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Novel TROP2 antibody\u2013drug conjugates for treatment of HER2-negative metastatic breast cancer patients with brain metastases: a promising option\u2606","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2025.105059","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"105059"}}